UTHR
United Therapeutics Corporation NASDAQ Listed Jun 17, 1999$472.21
Pre-mkt
$472.00
-0.04%
Mkt Cap $20.0B
52w Low $409.07
31.5% of range
52w High $609.35
50d MA $514.08
200d MA $524.55
P/E (TTM)
15.8x
EV/EBITDA
13.2x
P/B
3.0x
Debt/Equity
0.0x
ROE
18.8%
P/FCF
21.7x
RSI (14)
38.20
ATR (14)
$11.57
Beta
0.75
50d MA
$514.08
200d MA
$524.55
Avg Volume
627.1K
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
1040 Spring Street · Silver Spring, MD 20910 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | BMO | 6.86 | 7.27 | +6.0% | 518.68 | -2.6% | +0.1% | +2.7% | +1.1% | -1.7% | -2.7% | — |
| May 6, 2026 | BMO | 7.00 | 5.82 | -16.9% | 596.76 | +0.4% | -4.6% | -0.7% | +0.9% | +2.1% | -0.4% | — |
| Feb 25, 2026 | BMO | 7.13 | 7.70 | +8.0% | 473.43 | +1.4% | +13.0% | -5.9% | +0.1% | +2.0% | -3.0% | — |
| Oct 29, 2025 | BMO | 6.89 | 7.16 | +3.9% | 415.34 | +0.0% | +9.6% | -0.4% | -1.8% | -1.5% | -0.3% | — |
| Jul 30, 2025 | BMO | 7.29 | 6.41 | -12.1% | 297.56 | -4.0% | -5.2% | -2.6% | +7.1% | -0.6% | +4.2% | — |
| Apr 30, 2025 | BMO | 6.29 | 6.63 | +5.4% | 300.76 | +5.4% | +0.8% | -3.0% | +0.3% | +1.4% | -1.2% | — |
| Feb 26, 2025 | BMO | 6.40 | 6.19 | -3.3% | 357.50 | -3.9% | -10.8% | +1.5% | -1.1% | -3.1% | -0.5% | — |
| Oct 30, 2024 | BMO | 6.43 | 6.39 | -0.6% | 352.80 | +1.1% | +2.4% | +3.5% | +0.0% | +0.7% | +1.6% | — |
| Jul 31, 2024 | BMO | 6.40 | 5.85 | -8.6% | 337.54 | -5.0% | -7.2% | +4.6% | -0.0% | -0.6% | -1.2% | — |
| May 1, 2024 | BMO | 5.65 | 6.17 | +9.2% | 234.33 | +3.7% | +8.9% | +1.2% | +1.7% | -0.7% | +2.2% | — |
| Feb 21, 2024 | BMO | 4.19 | 4.36 | +4.1% | 214.16 | +2.6% | +2.3% | -0.7% | +4.3% | -1.5% | +1.4% | — |
| Nov 1, 2023 | BMO | 5.04 | 5.38 | +6.7% | 222.86 | -5.0% | +0.5% | +1.8% | -1.6% | +1.7% | +1.0% | — |
| Aug 2, 2023 | BMO | 4.51 | 5.24 | +16.2% | 240.13 | +8.3% | +0.3% | -3.7% | +1.9% | +0.6% | -0.4% | — |
| May 3, 2023 | BMO | 4.52 | 4.86 | +7.5% | 228.79 | -3.8% | -4.5% | -1.2% | -0.7% | -1.7% | -0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 24 | Goldman | Initiates | Sell | $321 | $489.42 | $472.71 | -3.4% | -3.5% | — | — | — | — |
| May 7 | Wells Fargo | Upgrade | Equal Weight → Overweight | $735 | $596.76 | $599.00 | +0.4% | -4.6% | -0.7% | +0.9% | +2.1% | -0.4% |
| Apr 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $574.77 | $576.06 | +0.2% | -0.5% | +1.0% | +0.2% | -0.2% | +0.5% |
| Mar 31 | BofA Securities | Maintains | Neutral → Neutral | — | $588.36 | $583.62 | -0.8% | +0.8% | -3.8% | -1.0% | -0.9% | +1.1% |
| Mar 31 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $588.36 | $583.62 | -0.8% | +0.8% | -3.8% | -1.0% | -0.9% | +1.1% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $588.36 | $583.62 | -0.8% | +0.8% | -3.8% | -1.0% | -0.9% | +1.1% |
| Mar 30 | TD Cowen | Maintains | Buy → Buy | — | $522.83 | $605.22 | +15.8% | +12.5% | +0.8% | -3.8% | -1.0% | -0.9% |
| Mar 23 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $524.28 | $529.02 | +0.9% | -0.6% | +2.0% | +1.8% | -1.7% | -1.8% |
| Mar 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $544.71 | $539.84 | -0.9% | -2.2% | +0.6% | -0.3% | +1.1% | -1.8% |
| Mar 5 | UBS | Maintains | Buy → Buy | — | $490.21 | $490.00 | -0.0% | -1.1% | -1.4% | +10.7% | +1.3% | +1.7% |
| Feb 26 | Oppenheimer | Maintains | Outperform → Outperform | — | $535.10 | $530.01 | -1.0% | -5.9% | +0.1% | +2.0% | -3.0% | -1.7% |
| Feb 26 | RBC Capital | Maintains | Outperform → Outperform | — | $535.10 | $530.01 | -1.0% | -5.9% | +0.1% | +2.0% | -3.0% | -1.7% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $535.10 | $530.01 | -1.0% | -5.9% | +0.1% | +2.0% | -3.0% | -1.7% |
| Feb 26 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $535.10 | $530.01 | -1.0% | -5.9% | +0.1% | +2.0% | -3.0% | -1.7% |
| Feb 26 | TD Cowen | Maintains | Buy → Buy | — | $535.10 | $530.01 | -1.0% | -5.9% | +0.1% | +2.0% | -3.0% | -1.7% |
| Jan 6 | UBS | Maintains | Buy → Buy | — | $489.69 | $495.01 | +1.1% | +2.7% | +0.2% | -2.6% | -1.5% | -0.2% |
| Nov 6 | UBS | Maintains | Buy → Buy | — | $447.45 | $448.00 | +0.1% | +1.5% | -1.1% | +1.1% | +1.2% | +0.5% |
| Oct 30 | RBC Capital | Maintains | Outperform → Outperform | — | $455.32 | $451.29 | -0.9% | -0.4% | -1.8% | -1.5% | -0.3% | +2.3% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $455.32 | $451.29 | -0.9% | -0.4% | -1.8% | -1.5% | -0.3% | +2.3% |
| Oct 30 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $455.32 | $451.29 | -0.9% | -0.4% | -1.8% | -1.5% | -0.3% | +2.3% |
| Oct 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $445.38 | $445.66 | +0.1% | -1.2% | +0.0% | -1.5% | -0.3% | +0.1% |
| Sep 29 | UBS | Maintains | Buy → Buy | — | $432.66 | $429.18 | -0.8% | -1.9% | -1.2% | +4.5% | +1.2% | +2.2% |
| Sep 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $403.80 | $404.98 | +0.3% | -1.8% | +2.1% | +0.0% | -0.5% | -1.3% |
| Sep 5 | Oppenheimer | Maintains | Outperform → Outperform | — | $380.47 | $375.61 | -1.3% | +5.3% | -1.5% | +2.3% | -1.8% | +2.1% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $380.47 | $375.61 | -1.3% | +5.3% | -1.5% | +2.3% | -1.8% | +2.1% |
| Sep 4 | UBS | Maintains | Buy → Buy | — | $391.45 | $395.60 | +1.1% | -2.8% | +5.3% | -1.5% | +2.3% | -1.8% |
| Sep 3 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $404.81 | $402.61 | -0.5% | -3.3% | -2.8% | +5.3% | -1.5% | +2.3% |
| Sep 2 | BofA Securities | Maintains | Neutral → Neutral | — | $304.76 | $419.63 | +37.7% | +32.8% | -3.3% | -2.8% | +5.3% | -1.5% |
| Sep 2 | Jefferies | Maintains | Buy → Buy | — | $304.76 | $419.63 | +37.7% | +32.8% | -3.3% | -2.8% | +5.3% | -1.5% |
| Aug 13 | UBS | Maintains | Buy → Buy | — | $301.39 | $302.96 | +0.5% | +2.8% | +0.8% | +0.3% | +0.3% | -0.3% |
| Jul 31 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $281.95 | $283.25 | +0.5% | -2.6% | +7.1% | -0.6% | +4.2% | -0.8% |
| Jul 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $281.95 | $283.25 | +0.5% | -2.6% | +7.1% | -0.6% | +4.2% | -0.8% |
| Jul 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $300.56 | $300.00 | -0.2% | -0.1% | -1.5% | +0.7% | -1.5% | +1.7% |
| Jul 8 | JP Morgan | Maintains | Overweight → Overweight | — | $290.39 | $290.53 | +0.0% | +1.4% | +2.1% | -0.1% | -1.5% | +0.7% |
| Jun 30 | UBS | Maintains | Buy → Buy | — | $284.27 | $285.75 | +0.5% | +1.1% | +1.2% | +1.5% | -0.2% | -1.4% |
| Jun 11 | BofA Securities | Maintains | Neutral → Neutral | — | $281.36 | $282.01 | +0.2% | -1.7% | +3.5% | -1.0% | +1.8% | -0.6% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $294.60 | $294.52 | -0.0% | +1.4% | -1.2% | +4.0% | +0.4% | -2.1% |
| May 1 | BofA Securities | Maintains | Neutral → Neutral | — | $303.09 | $304.79 | +0.6% | -3.0% | +0.3% | +1.4% | -1.2% | +4.0% |
| May 1 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $303.09 | $304.79 | +0.6% | -3.0% | +0.3% | +1.4% | -1.2% | +4.0% |
| May 1 | JP Morgan | Maintains | Overweight → Overweight | — | $303.09 | $304.79 | +0.6% | -3.0% | +0.3% | +1.4% | -1.2% | +4.0% |
| Apr 25 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $296.42 | $290.31 | -2.1% | -1.7% | +1.9% | +1.3% | +0.8% | -3.0% |
| Apr 21 | JP Morgan | Maintains | Overweight → Overweight | — | $284.73 | $285.57 | +0.3% | -0.2% | +3.0% | +0.2% | +1.0% | -1.7% |
| Apr 21 | BofA Securities | Upgrade | Underperform → Neutral | — | $284.73 | $285.57 | +0.3% | -0.2% | +3.0% | +0.2% | +1.0% | -1.7% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $318.89 | $318.80 | -0.0% | +1.5% | -1.1% | -3.1% | -0.5% | +0.8% |
| Jan 8 | UBS | Maintains | Buy → Buy | — | $362.33 | $363.99 | +0.5% | +1.2% | -0.4% | -0.6% | +0.5% | -0.8% |
| Nov 1 | Goldman Sachs | Maintains | Neutral → Neutral | — | $373.97 | $375.78 | +0.5% | +0.0% | +0.7% | +1.6% | +3.8% | +1.3% |
| Oct 31 | Argus | Maintains | Buy → Buy | — | $361.40 | $362.54 | +0.3% | +3.5% | +0.0% | +0.7% | +1.6% | +3.8% |
| Oct 31 | Oppenheimer | Maintains | Outperform → Outperform | — | $361.40 | $362.54 | +0.3% | +3.5% | +0.0% | +0.7% | +1.6% | +3.8% |
| Oct 31 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $361.40 | $362.54 | +0.3% | +3.5% | +0.0% | +0.7% | +1.6% | +3.8% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $361.40 | $362.54 | +0.3% | +3.5% | +0.0% | +0.7% | +1.6% | +3.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 240 | $500.05 | $120K | 324,443 | — | — |
| Sep 23, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 90 | $498.90 | $45K | 324,683 | — | — |
| Sep 23, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 270 | $498.38 | $135K | 324,773 | — | — |
| Sep 23, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 766 | $497.27 | $381K | 325,043 | — | — |
| Sep 23, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 525 | $496.38 | $261K | 325,809 | — | — |
| Sep 23, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 155 | $495.17 | $77K | 326,334 | — | — |
| Sep 23, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 160 | $493.72 | $79K | 326,489 | — | — |
| Sep 23, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 480 | $492.54 | $236K | 326,649 | — | — |
| Sep 23, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 824 | $491.65 | $405K | 327,129 | — | — |
| Sep 23, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 1,440 | $490.48 | $706K | 327,953 | — | — |
| Sep 23, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 2,162 | $489.52 | $1.1M | 329,393 | — | — |
| Sep 23, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 2,388 | $488.70 | $1.2M | 331,555 | — | — |
| Sep 22, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 160 | $499.07 | $80K | 324,443 | -3.52% | — |
| Sep 22, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 1,358 | $497.73 | $676K | 324,603 | -3.52% | — |
| Sep 22, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 1,484 | $496.83 | $737K | 325,961 | -3.52% | — |
| Sep 22, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 1,488 | $495.77 | $738K | 327,445 | -3.52% | — |
| Sep 22, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 1,337 | $494.66 | $661K | 328,933 | -3.52% | — |
| Sep 22, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 1,645 | $493.70 | $812K | 330,270 | -3.52% | — |
| Sep 22, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 628 | $492.67 | $309K | 331,915 | -3.52% | — |
| Sep 22, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 736 | $491.45 | $362K | 332,543 | -3.52% | — |
| Sep 22, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 424 | $490.54 | $208K | 333,279 | -3.52% | — |
| Sep 22, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 240 | $489.61 | $118K | 333,703 | -3.52% | — |
| Sep 21, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 843 | $496.62 | $419K | 324,443 | -1.64% | — |
| Sep 21, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 2,287 | $495.71 | $1.1M | 325,286 | -1.64% | — |
| Sep 21, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 2,170 | $494.82 | $1.1M | 327,573 | -1.64% | — |
| Sep 21, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 2,680 | $493.60 | $1.3M | 329,743 | -1.64% | — |
| Sep 21, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 1,520 | $492.97 | $749K | 332,423 | -1.64% | — |
| Sep 18, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 160 | $498.25 | $80K | 324,443 | +0.91% | — |
| Sep 18, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 277 | $496.64 | $138K | 324,603 | +0.91% | — |
| Sep 18, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 2,330 | $495.66 | $1.2M | 324,880 | +0.91% | — |
8-K · 5.02
!!! Very High
United Therapeutics Corporation -- 8-K 5.02: Executive Change
Jul 23
8-K · 2.02
!! High
United Therapeutics Corporation -- 8-K 2.02: Earnings Results
United Therapeutics reported first-quarter 2026 earnings on May 6, 2026, providing investors with updated financial performance and operational metrics for the period ended March 31.
May 6
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Nebulized Tyvaso's positive Phase 3 results for IPF treatment validate United Therapeutics' pipeline and could drive significant revenue growth if approved, supporting stock appreciation.
Mar 30
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A new CPA executive appointment suggests improved financial controls and accounting rigor, which could enhance investor confidence and potentially support stock stability, particularly relevant for smaller-cap companies like SNBR and UTHR.
Mar 12
8-K · 1.01
!! High
United Therapeutics Corp -- 8-K 1.01: Material Agreement
United Therapeutics authorized a $2 billion share repurchase program and immediately entered into accelerated share repurchase agreements with Citibank, signaling management confidence and potentially supporting stock prices through reduced share count.
Mar 9
8-K · 7.01
! Medium
United Therapeutics Corp -- 8-K 7.01: Regulation FD Disclosure
United Therapeutics will host a webcast at 8:30 a.m. to present ADVANCE OUTCOMES trial results, potentially providing investors with significant clinical data regarding a key pipeline program.
Mar 2
8-K
Mannkind Corporation -- 8-K Filing
MannKind's Furoscix ReadyFlow Autoinjector will receive FDA review completion by July 26, 2026, potentially expanding its commercial portfolio and supporting future revenue growth if approved.
Feb 26
8-K
United Therapeutics Corp -- 8-K Filing
United Therapeutics achieved record $3.18 billion in 2025 revenues, representing 11% year-over-year growth, signaling strong commercial momentum across its product portfolio for investors.
Feb 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Blackrock, Inc. | 5,294,529 | $2.9B | New | Jun 2026 |
| 2 | Avoro Capital Advisors Llc | 2,630,000 | $1.6B | Added | Mar 2026 |
| 3 | Vanguard Portfolio Management Llc | 1,919,429 | $1.0B | Reduced | Jun 2026 |
| 4 | Vanguard Capital Management Llc | 1,918,256 | $1.0B | Reduced | Jun 2026 |
| 5 | Renaissance Technologies Llc | 1,708,739 | $926M | Reduced | Jun 2026 |
| 6 | Janus Henderson Group Plc | 866,930 | $514M | New | Mar 2026 |
| 7 | Morgan Stanley | 778,550 | $379M | Reduced | Dec 2025 |
| 8 | Norges Bank | 694,753 | $376M | New | Jun 2026 |
| 9 | Invesco Ltd. | 608,367 | $361M | — | Mar 2026 |
| 10 | Assetmark, Inc | 624,068 | $338M | Reduced | Jun 2026 |
| 11 | Citadel Advisors Llc | 609,384 | $330M | Reduced | Jun 2026 |
| 12 | Fmr Llc | 528,346 | $313M | Added | Mar 2026 |
| 13 | Aqr Capital Management Llc | 546,002 | $295M | Reduced | Jun 2026 |
| 14 | Deerfield Management Company, L.p. | 457,000 | $271M | Added | Mar 2026 |
| 15 | Northern Trust Corp | 436,566 | $259M | Added | Mar 2026 |
| 16 | Millennium Management Llc | 409,074 | $222M | Added | Jun 2026 |
| 17 | Bank Of New York Mellon Corp | 329,148 | $195M | Reduced | Mar 2026 |
| 18 | Acadian Asset Management Llc | 300,204 | $178M | Added | Mar 2026 |
| 19 | Swedbank Ab | 322,995 | $175M | Reduced | Jun 2026 |
| 20 | Jpmorgan Chase & Co | 291,621 | $172M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$20.04B
Enterprise Value
$21.89B
P/E (TTM)
15.85x
Forward P/E
16.08x
PEG Ratio
1.16x
P/B
2.95x
P/S
7.17x
P/FCF
21.73x
EV/EBITDA
13.25x
Shares Out
47.9M
Financials (TTM)
Revenue
$3.15B
Net Income
$1.31B
EBITDA
$1.65B
Free Cash Flow
$1.04B
Op Cash Flow
$1.56B
EPS Basic
$30.13
EPS Diluted
$27.91
EPS Forward
$29.37
Gross Margin
86.1%
Op Margin
44.5%
Net Margin
41.6%
Balance Sheet
Total Assets
$7.88B
Total Liab.
$783.8M
Total Equity
$7.10B
Cash
$1.56B
LT Debt
$0
Book Value/Sh
$160.19
Debt/Equity
0.00x
Current Ratio
6.60
Quick Ratio
6.28
Returns & Growth
ROE
18.8%
ROA
16.9%
ROIC
15.9%
Rev Growth YoY
+10.6%
EPS Growth YoY
+14.0%
Price Returns
2W
-6.3%
1M
-8.9%
3M
-13.1%
6M
-12.8%
12M
+11.0%
Technicals
52W High
$609.35
52W Low
$409.07
50d MA
$514.08
200d MA
$524.55
RSI (14)
38.20
ATR (14)
$11.57
Beta
0.75
Avg Volume
627K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$610.67
High
$700.00
Low
$519.00
Median
$612.50
Data updated apr 27, 2026 7:10am
· Source: financialmodelingprep.com